Page 5,968«..1020..5,9675,9685,9695,970..5,9805,990..»

Customer Gets Harassed At Walmart (North York) – Video

Posted: Published on December 18th, 2012

Customer Gets Harassed At Walmart (North York) Sunday December 16, 2012 - A customer gets harassed for potentially stealing at the Walmart on Eglinton Pharmacy in North York, Ontario.From:Aly KViews:1 0ratingsTime:02:25More inEntertainment See the rest here: Customer Gets Harassed At Walmart (North York) - Video … Continue reading →

Posted in Pharmacy | Comments Off on Customer Gets Harassed At Walmart (North York) – Video

DDH Health Card – Video

Posted: Published on December 18th, 2012

DDH Health Card Thinking of a great gift? What would be more perfect that the gift of health. Introducing the DDH Health Card, the first gift card offered by Davao Doctors Hospital. Use it when availing Out Patient Services, Laboratory examinations, X-ray procedures and Pharmacy. Plus get more out of your card when you avail of our services in DDH Dumoy Satellite. Available in Php 1000 and Php 500 denominations. Treat your loved ones with a DDH Health Card today. To order, please call our Treasury Department at 221-2101 loc 121 or email us at info@ddh.com.phFrom:DavaoDocHospViews:0 0ratingsTime:02:03More inEducation See original here: DDH Health Card - Video … Continue reading →

Posted in Pharmacy | Comments Off on DDH Health Card – Video

UC launches new pharmacy degree

Posted: Published on December 18th, 2012

The University of Canberra (UC) is expanding its pharmacy program, providing more options for students. UC currently runs a Masters Degree in Pharmacy, where students who have already completed an undergraduate degree can apply for the program. Now the university has opened the program to school leavers, creating a bachelor degree. UC head of pharmacy Greg Kyle says he is not concerned about having too many graduates. "There's been a lot of talk about that. Good pharmacy students and good graduates will always find positions," he said. "I'm aware of some positions that have been difficult to fill not very far from here and a lot of our students, 25 to 30 per cent do end up working in rural areas. That's our experience from the Masters." Dr Kyle says the new program will accommodate up to 50 students. "We include rural placements and we provide a range of experiences for the students both city and rural based," he said. "Students in our new bachelor program will be able to benefit from placements in our mobile clinic, government departments, aged care facilities, GP clinics and of course community pharmacies. "The other opportunity for pharmacy with having more graduates, is it … Continue reading →

Posted in Pharmacy | Comments Off on UC launches new pharmacy degree

LCT and Otsuka to co-develop treatment for Parkinson's disease

Posted: Published on December 17th, 2012

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the signing of an agreement with Otsuka Pharmaceutical Factory, Inc. (Otsuka) to co-develop NTCELL for the treatment of Parkinsons disease and other neurological disorders. LCT will receive an upfront payment of A$3m within 30 days of signing. In addition, Otsuka will fund all development costs, estimated at $2m, to complete the previously announced Phase I trial of NTCELL in Parkinsons disease. LCT will receive a further milestone payment of $2m when the first patient in the Phase I Parkinsons trial has been safely implanted with NTCELL. This is expected to occur in the second quarter of 2013. In return, LCT has granted Otsuka an exclusive option to jointly develop and commercialise NTCELL in Parkinsons and other neurological diseases, including hearing loss, through Diatranz Otsuka Limited (DOL), the 50:50 joint venture formed between LCT and Otsuka. If Otsuka exercises this option it will subscribe for $20 million of additional equity into DOL to fund the ongoing development of NTCELL in Parkinsons disease through to market approval and to further develop NTCELL in other neurological diseases. At the same time LCT will transfer the intellectual property for therapeutic use of NTCELL in … Continue reading →

Posted in Parkinson's Treatment | Comments Off on LCT and Otsuka to co-develop treatment for Parkinson's disease

Pin prick test will reduce HIV infection

Posted: Published on December 17th, 2012

A new rapid test for HIV will increase the number of people being tested for the disease and reduce the risk of transmission, Federal Health Minister Tanya Plibersek says. Ms Plibersek on Monday announced the Therapeutic Goods Administration (TGA) had approved for marketing the Alere Determine Combo HIV 1/2 Ag/Ab test, which will give people a preliminary result within 30 minutes. Ms Plibersek said the pin prick test would mean people newly infected with HIV can quickly access treatment, while the risk of infecting others would also be decreased. "This test doesn't replace the importance of safe sex practices and other harm reduction strategies in Australia," Ms Plibersek told reporters in Sydney. "What it does though is increase the likelihood that people will come in for a test, and increase the likelihood they'll be tested frequently. "Early diagnosis of any illness, means earlier treatment. "It is also very important for people to know their HIV status because we also reduce the risk of transmission." The current antibody tests can take between two weeks and three months. Ms Plibersek said TGA approval had come with strict accreditation conditions to ensure clinics carrying out the tests were trained to not only offer … Continue reading →

Posted in MS Treatment | Comments Off on Pin prick test will reduce HIV infection

Christchurch neurologist part of MS trial

Posted: Published on December 17th, 2012

A Christchurch neurologist is leading part of the worlds first clinical trial into whether oral vitamin D may prevent multiple sclerosis (MS). The trial is being conducted in both Australia and New Zealand and will include 240 people with early MS. Dr Deborah Mason will oversee the New Zealanders taking part in the study while Professor Bruce Taylor, a former Christchurch neurologist now based in Hobart, Australia, is one of the principal researchers heading the trial in Australia. Dr Mason says MS prevalence in New Zealand is high compared to many other parts of the world and appears to be increasing particularly in females. Researchers believe New Zealanders may be particularly susceptible to MS because of our low latitude which results in low levels of vitamin D. "This is particularly true for people living in Canterbury, Otago and Southland. We are uniquely placed to perform this research here and it has particular relevance given our high MS rates," Dr Mason says. "It will be the worlds first randomised controlled interventional study using vitamin D in people with MS to see how it might influence this disease." MS Research Australia has pledged $3.5 million towards the study. "This trial may not … Continue reading →

Posted in MS Treatment | Comments Off on Christchurch neurologist part of MS trial

Depersonalization / Derealization – How to Cope and Heal (Part 1) – Video

Posted: Published on December 17th, 2012

Depersonalization / Derealization - How to Cope and Heal (Part 1) Please SHARE THIS VIDEO if you found it useful or if you know somebody who is suffering and scared. Thank you. In this video I discus my experience with depersonalization, how I coped with my symptoms, and what helped me heal. MY STORY My name is Noah and on May 18 2011, I had a rare reaction to a vaccine called VIVITROL and consequently spiraled into a major, agitated, suicidal depression with depersonalization. I lost 25 lbs in 4 weeks and was in full panic or near panic for 8 weeks straight mixed with the darkest most painful depression I cold have ever imagined. I immediately could not work and had to move in with my parents who along with many siblings and friends had to watch me 24/7 as I was so suicidal. I was eventually hospitalized. Getting through each day seemed truly unbearable and I knew I would surely die. I have been put on many many different SSRI's SNRI's Tricyclics, Mood stabilizers, anti psychotics, holistic meds, acupuncture and even a form of shock therapy called RTMS. I barely saw any improvement in my condition … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Depersonalization / Derealization – How to Cope and Heal (Part 1) – Video

In The Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Posted: Published on December 17th, 2012

When cosmetic surgeon Allan Wu first heard the woman's complaint, he wondered if she was imagining things or making it up. A resident of Los Angeles in her late sixties, she explained that she could not open her right eye without considerable pain and that every time she forced it open, she heard a strange clicka sharp sound, like a tiny castanet snapping shut. After examining her in person at The Morrow Institute in Rancho Mirage, Calif., Wu could see that something was wrong: Her eyelid drooped stubbornly, and the area around her eye was somewhat swollen. Six and a half hours of surgery later, he and his colleagues had dug out small chunks of bone from the woman's eyelid and tissue surrounding her eye, which was scratched but largely intact. The clicks she heard were the bone fragments grinding against one another. About three months earlier the woman had opted for a relatively new kind of cosmetic procedure at a different clinic in Beverly Hillsa face-lift that made use of her own adult stem cells. First, cosmetic surgeons had removed some the woman's abdominal fat with liposuction and isolated the adult stem cells withina family of cells that can … Continue reading →

Posted in Stem Cell Research | Comments Off on In The Flesh: The Embedded Dangers of Untested Stem Cell Cosmetics

Entia Receives Canadian Patent Notice of Allowance for Use of Ergothioneine and its Genetic Transporter

Posted: Published on December 17th, 2012

SHERWOOD, Ore., Dec. 17, 2012 /PRNewswire/ -- Entia Biosciences (ERGO), a food science biotechnology company and emerging leader in the fields of Nutrigenomics and Targeted Nutrition, has received a Patent Notice of Allowance from the Canadian Intellectual Property Office covering the use of Ergothioneine and its genetic transporter (SLC22A4) in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Ergothioneine is a powerful amino acid and master antioxidant that is acquired exclusively from the diet and carried by this unique and specific transporter to cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Research conducted by Entia since 2011 has confirmed significant transporter activity in diabetes, arthritis, and several other serious non-communicable chronic conditions, suggesting an important physiologic role for Ergothioneine in diseases affecting millions of people world-wide. "We are very pleased that our intellectual property estate on Ergothioneine is advancing nicely alongside the scientific, clinical and other business developments at Entia," said Marvin S. Hausman MD, Chairman and Chief Executive Officer. "The issuance of this important foundational patent significantly enhances the commercialization strategy for our ErgoD2 line of proprietary medical foods, functional … Continue reading →

Comments Off on Entia Receives Canadian Patent Notice of Allowance for Use of Ergothioneine and its Genetic Transporter

Exclusive Agreement for Genetic Testing and Research Announced Between Dominion Diagnostics and LifeGen, Inc.

Posted: Published on December 17th, 2012

NORTH KINGSTOWN, R.I., Dec. 17, 2012 /PRNewswire/ --Dominion Diagnostics has entered into an exclusive agreement with LifeGen, Inc. for the licensing rights to patented genetic testing. Currently the two companies are involved in a research study aimed at validating the testing against the Addiction Severity Index (ASI) designed and marketed by Inflexxion, Inc. The research results are on track to be released in the first quarter of 2013, and are expected to show that LifeGen's test is valuable in determining a patient's Genetic Addiction Risk Score (GARS), or relative predisposition in manifesting addictive behaviors. Approximately 400 patient subjects selected from addiction treatment facilities across the country are involved in the GARS analysis. The GARS analysis is set to investigate a panel of genes primarily involved in brain reward circuitry. For 30% of the human population (approximately 100 million people), genetics are a large factor in dopamine-driven addiction. This subset of the population carries the DRD2 Type A1 receptor gene which induces low dopamine brain function that results in the propensity for addictive cravings. The GARS test involves a number of reward genes and related polymorphisms which have significant impact on substance use disorders. LifeGen's Kenneth Blum, PhD is the primary … Continue reading →

Comments Off on Exclusive Agreement for Genetic Testing and Research Announced Between Dominion Diagnostics and LifeGen, Inc.

Page 5,968«..1020..5,9675,9685,9695,970..5,9805,990..»